The higher incidence of fatal infections noted in the canakinumab group, the lack of an established role in the treatment of SLE and their expensive cost will, however, limit the use of IL-1 blockers for preventing atherosclerosis in SLE. This evidence concerns the gene IL1B and atherosclerosis.